Soc. Generale Call 54 SDZ 20.06.2.../ DE000SJ18WW8 /
| 12.11.2024 21:50:16 | Изменение-0.008 | Бид12.11.2024 | Предложение12.11.2024 | Базовый актив | Цена исполнения | Дата истечения | Тип опциона |
|---|---|---|---|---|---|---|---|
| 0.047EUR | -14.55% | - Величина цены спроса: - |
- Величина цены предложения: - |
SANDOZ GROUP N | 54.00 CHF | 20.06.2025 | Call |
GlobeNewswire
12.08
Sandoz receives FDA approval for Enzeevu™ (aflibercept-abzv), further strengthening US biosimilar po...
GlobeNewswire
25.07
Sandoz launches biosimilar Pyzchiva® (ustekinumab) across Europe, to treat chronic inflammatory dise...
GlobeNewswire
01.07
FDA approves biosimilar Pyzchiva® (ustekinumab-ttwe), to be commercialized by Sandoz in US
GlobeNewswire
22.05
Sandoz receives European Commission approval for Wyost® and Jubbonti®, the first and only biosimilar...
GlobeNewswire
30.04
Shareholders approve all resolutions proposed by Board of Directors at Annual General Meeting of San...
GlobeNewswire
30.04
Sandoz reaches agreement with Amgen resolving all patent litigation related to its US denosumab bios...
GlobeNewswire
22.04
Sandoz confirms European Commission approval of Pyzchiva® (ustekinumab), further strengthening immun...
GlobeNewswire
21.03
Sandoz opens new antibiotic production facility in Austria, to significantly increase capacity for l...
GlobeNewswire
04.03
Sandoz acquires CIMERLI® business from Coherus, further building biosimilar and ophthalmology leader...
GlobeNewswire
29.02
Sandoz US subsidiaries resolve generic drug antitrust class action litigation with direct purchaser ...
GlobeNewswire
31.01
Sandoz launches first and only biosimilar for multiple sclerosis, Tyruko® (natalizumab), in Germany
GlobeNewswire
22.01
Sandoz announces agreement to acquire CIMERLI® business from Coherus, strengthening position in US m...
GlobeNewswire
21.11.2023
Sandoz launches Hyrimoz® (adalimumab) high-concentration formulation in Europe, aiming to improve pa...
- Первая страница
- Назад
- 1
- 2
- Следующий
- Последняя страница
